Carmat: Invest Securities reduces target price
(CercleFinance.com) - Invest Securities maintains its 'buy' recommendation on Carmat, but significantly reduces its target price from E10 to E7.
6, following the new financial extension obtained by the medical technology company, in the form of a financing line.
This downward revision is mainly based on the increase in beta, to reflect Carmat's difficulties in significantly strengthening its financial visibility, when the dilutive impact of the financing line was already largely built into its model.
The broker nevertheless welcomes an encouraging half-year update, marked by a doubling of the implantation rate compared with Q1, with the guidance assuming a further strong acceleration in H2.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
6, following the new financial extension obtained by the medical technology company, in the form of a financing line.
This downward revision is mainly based on the increase in beta, to reflect Carmat's difficulties in significantly strengthening its financial visibility, when the dilutive impact of the financing line was already largely built into its model.
The broker nevertheless welcomes an encouraging half-year update, marked by a doubling of the implantation rate compared with Q1, with the guidance assuming a further strong acceleration in H2.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.